Welcome to our dedicated page for BRISTOL MYERS SQUIBB CO SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
Bristol Myers Squibb director Theodore R. Samuels II reported an automatic grant of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. After this award, he beneficially owns 67,882.504 Deferred Share Units in total.
Each Deferred Share Unit converts into one share of common stock when settled. These units become settleable when he ceases to be a director or on a future date he previously selected, and the total includes deferred compensation and reinvested dividends under the company’s deferred compensation plan for non-employee directors.
Bristol Myers Squibb director Derica W. Rice reported an award of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. This increased his holdings of Deferred Share Units to 39,324.809, which track common stock and are settled in shares later.
Each Deferred Share Unit converts into one share of common stock when he leaves the board or on a future date he previously selected. The holdings also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit. Following this award, she beneficially owns 25,498.163 Deferred Share Units, held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Price ceases to be a director or at a future date she previously specified, and include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen reported an acquisition of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. Following this transaction, he beneficially owns 14,979.689 Deferred Share Units directly.
Each Deferred Share Unit will convert into one share of common stock upon settlement, which occurs when McMullen ceases to be a director or at a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Manuel Hidalgo Medina reported an award of 3,996.367 Deferred Share Units on common stock, effective February 1, 2026, at a reference price of $55.05 per unit. Following this grant, he holds 22,763.938 Deferred Share Units in total, all reported as directly owned.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. According to the disclosure, these units become settleable when he ceases to be a director or on a future date he previously specified. The total also reflects deferred compensation and dividends that have been reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Julia Haller reported a grant of deferred share units. On 02/01/2026 she acquired 3,996.367 deferred share units at $55.05 each, bringing her total to 37,903.154 derivative securities held directly. Each unit will convert into one share of common stock when she ceases to be a director or at a future date she previously selected.
The holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors, showing this is board compensation structured in stock-linked form rather than a cash payment.
Bristol Myers Squibb director Deepak Bhatt reported an award of 3,996.367 Deferred Share Units on February 1, 2026, at a reference price of $55.05 per unit. After this transaction, he beneficially owned 19,241.818 Deferred Share Units held directly.
Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. These units become settleable when Bhatt ceases to be a director or at a future date he previously specified, and the total includes deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini reported an equity compensation grant. On February 1, 2026, he was awarded 3,996.367 Deferred Share Units at $55.05 per unit, increasing his total holdings to 70,858.084 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the award is settled. The units become settleable when Arduini ceases to be a director or on a future date he previously selected. The reported balance includes deferred compensation and dividends reinvested under the company’s deferred compensation plan for non-employee directors.
Bristol-Myers Squibb Company reported that it has made a new investor presentation available on its website as of January 12, 2026. The company furnished this presentation as Exhibit 99.1 to a current report, giving investors another source of information about its business and outlook. The report explains that this information is being furnished under disclosure rules and is not considered filed for liability purposes or automatically incorporated into other regulatory documents.
Bristol-Myers Squibb director Phyllis R. Yale reported additional deferred share units tied to company stock. On 12/31/2025, she acquired 648.869 Deferred Share Units, each linked to one share of Bristol-Myers Squibb common stock at a $0 exercise price. After this transaction, she beneficially owned 38,891.933 deferred share units in total, held directly.
The deferred share units are part of the 1987 Deferred Compensation Plan for Non-Employee Directors and include both deferred compensation and dividends that have been reinvested. These units will convert into shares of common stock when she ceases to be a director or at a future date she previously selected, meaning the economic value is tied to the company’s share performance over time.